| Business Summary | | Schering
AG
is
a
global
research-based
company
engaged
in
the
discovery,
development,
manufacture,
marketing
and
sale
of
pharmaceutical
products.
The
Company
operates
nine
research
and
development
centers
in
Europe,
the
United
States
and
Japan;
produces
products
in
over
20
facilities
located
in
Europe,
United
States,
Latin
America
and
Asia;
and
markets
and
sells
its
products
in
over
100
countries
worldwide.
The
Company's
focused
product
portfolio
is
comprised
of
products
from
its
four
core
business
areas:
Fertility
Control
and
Hormone
Therapy,
Therapeutics
for
selected
disabling
and
life-threatening
conditions,
Diagnostic
and
Radiopharmaceuticals
and
Dermatology.
The
Company
also
participates
in
the
crop
protection
and
crop
production
business.
The
Company
manages
its
businesses
on
a
geographic
basis,
and
its
pharmaceutical
business
consists
of
five
geographic
segments:
Europe,
the
United
States,
Latin
America/Canada,
Japan
and
Asia. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Schering
AG
is
a
global
research-based
company
engaged
in
the
discovery,
development,
manufacture,
sale
and
marketing
of
pharmaceutical
products
primarily
concentrated
on
the
exploitation
of
novel
technologies
for
unmet
medical
needs.
For
the
six
months
ended
6/30/01,
revenues
rose
9%
to
EUR2.41
billion.
Net
income
rose
26%
to
EUR264M.
Revenues
reflect
acquisitions.
Higher
income
also
reflects
higher
income
from
Aventis
CropScience. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Giuseppe Vita, 65 | Chairman
of the Supervisory Board | Hubertus Erlen, 57 | CEO | Norbert Deutschmann, 49 | Vice
Chairman of the Supervisory Board | Jurgen Wingefeld, 57 | Vice
Chairman of the Supervisory Board | Ulrich Kostlin, 48 | Member
of the Exec. Board |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|